BCTX.US Briacell Therapeutics Corp

Healthcare Biotechnology USA Stocks
3.39 USD
Close of Nov 14, 2026
2.60 13.09
Market cap
USD 29.6M
P/E
-
P/B
1.87x
ROE
-212.8%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the fiscal year ending Jul 2026.

Is BCTX.US undervalued?

Graham number

The Graham number of Briacell Therapeutics Corp cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Briacell Therapeutics Corp fundamental analysis

No fundamental analysis for Briacell Therapeutics Corp yet.

Briacell Therapeutics Corp stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Briacell Therapeutics Corp

BriaCell Therapeutics Corp., a pre-clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted immunotherapy program against end-stage breast cancer that is in Phase 3 clinical trials. The company develops Bria-OTS, a personalized off-the-shelf immunotherapy; and a soluble CD80 protein therapeutic that acts as a stimulator of the immune system and an immune checkpoint inhibitor. I…

Full company profile